最新ニュース Palisade Bio (NASDAQ:PALI) 株価情報

Palisade Bio

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Palisade Bio Inc

PALIBURG HOLDINGS LTD by PALIBURG HOLDINGS LTD.

PALISADES GOLDCORP LTD by PALISADES GOLDCORP LTD.

Palisades Goldcorp Ltd

Stephens &amp; Co. analyst Russell Gunther maintains Seacoast Banking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBCF#NASDAQ">SBCF</a>) with a Equal-Weight and lowers the price target from $28 to $26.

News

Price Target

Analyst Ratings

SBCF

Stephens & Co. Maintains Equal-Weight on Seacoast Banking, Lowers Price Target to $26

Wells Fargo analyst Finian O'Shea maintains Bain Capital Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCSF#NYSE">BCSF</a>) with a Overweight and lowers the price target from $19 to $16.

BCSF

Wells Fargo Maintains Overweight on Bain Capital Specialty, Lowers Price Target to $16

Wells Fargo analyst Finian O'Shea maintains Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) with a Overweight and lowers the price target from $23 to $22.

ARCC

Wells Fargo Maintains Overweight on Ares Capital, Lowers Price Target to $22

Wells Fargo analyst Timur Braziler maintains First BanCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBP#NYSE">FBP</a>) with a Overweight and raises the price target from $20 to $22.

Wells Fargo Maintains Overweight on First BanCorp, Raises Price Target to $22

Wells Fargo analyst Roger Read maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Overweight and lowers the price target from $162 to $149.

Wells Fargo Maintains Overweight on Phillips 66, Lowers Price Target to $149

In a development that might reshape XRP&#8217;s position in traditional finance, the U.S. Securities and Exchange Commission (SEC) has cleared ProShares&#8217; proposal to list <a href="https://www.benzinga.com/etfs">XRP futures ETFs</a>. 
Slated to list on April 30, the new funds might provide investors with a new, regulated way to ride, or bet against, the choppy currents of crypto&#8217;s third-largest asset.
Market responses have been prompt. XRP jumped to $2.32 in early trading on April 28, an increase of 6.5%, on <a href="https://coinmarketcap.com/currencies/xrp/">CoinMarketCap</a>. Its market capitalization went up to $135.6 billion, with trading volume rising by over 172% within the last 24 hours.
ProShares, a well-known name in Bitcoin ETFs, initially floated the XRP futures ETFs in January — just as President Donald Trump, who <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44907123/ripple-coinbase-solana-among-crypto-firms-contributing-over-12m-to-trumps-inauguration-fund">received massive donations</a> from Ripple, was sworn into office. Ripple created and maintains the XRP Ledger and the XRP token.
ProShares&#8217; XRP products aim to provide a variety of strategies, from leveraged exposure to bearish bets, all connected to the XRP Index.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44683138/xrp-will-overtake-ethereum-by-2028-standard-chartered">XRP Will Overtake Ethereum By 2028: Standard Chartered</a>
While ProShares&#8217; news is making headlines, it&#8217;s not necessarily a first-mover benefit. Earlier this month, <a href="https://www.benzinga.com/25/04/44721421/exclusive-from-corn-to-crypto-teucrium-ceo-talks-strategy-risk-and-the-launch-of-xxrp">Teucrium rolled out its own XRP focused ETF</a>, the Teucrium 2x Long Daily XRP ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XXRP#NYSE">XXRP</a>) on the NYSE, beating ProShares in and stepping up the stakes in what&#8217;s becoming a battle to control the XRP ETF space.
In addition to futures, ProShares has also filed for an XRP spot ETF, a fund that would mirror the true price of the token, not derivatives — but that is still pending with the SEC. In the meantime, Brazil has beaten everybody to the punch, approving Hashdex&#8217;s spot XRP ETF last week, highlighting how some overseas markets are racing ahead while the U.S. regulatory machine grinds along a bit more slowly.
Adding further velocity to XRP&#8217;s institutional rally, Reuters reported that <a href="https://in.benzinga.com/markets/cryptocurrency/25/04/44984259/cme-group-to-launch-xrp-futures-in-may-how-did-xrp-price-react">CME Group plans to bring XRP futures contracts</a> to the market on May 19 to diversify beyond Bitcoin and Ethereum.
It is important to understand the distinction between a futures ETF and a spot ETF. A futures ETF does not entail owning XRP directly. Rather, it provides a way for investors to wager on what direction XRP&#8217;s price will move, providing exposure without the inconvenience of crypto wallets, private keys, or the shadow of hacking scandals. It&#8217;s a neater, albeit occasionally more expensive, means of gambling on the future of a digital asset.
The SEC&#8217;s endorsement is being touted as another move toward mainstreaming crypto in traditional financial systems. Institutional investors, previously hesitant to wade into the <a href="https://www.benzinga.com/topic/cryptocurrencies">turbulent seas of cryptocurrency</a>, are starting to dip their toes in. Reuters cited growing institutional demand for Solana and XRP after similar ETF approvals, a trend that might increase speed if additional products are approved.
XRP seems to be lapping up the limelight, an unusual solo performance in a market more typically dominated by Bitcoin&#8217;s every step. Whether this bull run has substance or is merely a pre-launch party time remains to be discovered. But one thing is sure: with futures ETFs on the horizon and institutional doors creaking ajar, Ripple&#8217;s token has bigger quarters waiting for it.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/45038430/massive-power-outages-hit-spain-portugal-snarling-travel-investigations-into-cause-underway">Massive Power Outages Hit Spain, Portugal Snarling Travel: Investigations Into Cause Underway</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

New ETFs

ETFs

Listed Funds Trust Teucrium 2x Long Daily XRP ETF

XXRP

SEC Approves ProShares XRP Futures ETFs: XRP Price Surges Ahead Of Launch

BuzzFeed, Inc. is expanding inventory to retail media buyers with a new partnership with Shopsense AI. As the first editorial media brand to partner with Shopsense, BuzzFeed will use the company's AI-powered Commerce Operating System (OS) to integrate context-aware product recommendations directly into articles — giving BuzzFeed's monthly audience of 71 million monthly U.S. visitors a seamless way to explore and purchase products relevant to the lifestyle, fashion, and entertainment content they're consuming.

BZFD

BuzzFeed Partners With Shopsense AI To Deliver Context-Aware Shopping Recommendations To U.S. Visitors, Expanding Retail Media Inventory

Stephens &amp; Co. analyst Trey Grooms maintains Pool (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) with a Overweight and lowers the price target from $400 to $350.

POOL

Stephens & Co. Maintains Overweight on Pool, Lowers Price Target to $350

Domino's Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) shares were trading lower on Monday after the company reported its first-quarter FY25 earnings.
The company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45034195/dominos-pizza-announces-first-quarter-2025-financial-results" rel="noreferrer noopener">first-quarter revenue growth of 2.5%</a> year over year to $1.11 billion, missing the analyst consensus estimate of $1.13 billion. EPS of $4.33 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus</a> estimate of $4.07.
The revenue increase was primarily due to higher U.S. franchise advertising revenues, higher supply chain revenues and higher international franchise royalties and fees.&nbsp;
The growth in supply chain revenues was attributable to an increase in the company's food basket pricing to stores, which increased 4.8% during the first quarter of 2025 as compared to the first quarter of 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/restaurants/25/04/45021992/us-restaurants-face-growth-hurdles-as-macro-headwinds-mount-says-analyst" rel="noreferrer noopener">US Restaurants Face Growth Hurdles As Macro Headwinds Mount, Says Analyst</a>
Global retail sales increased 4.7%, excluding the impact of foreign currency. Same-store sales in the U.S. fell 0.5%, while International same-store sales (excluding foreign currency impact) increased 3.7%.
The company's global net store count decreased by eight stores. Gross margin for the quarter expanded 90 basis points to 39.8%, while operating margin contracted 50 basis points to 18.9%.
Operating cash flow for the quarter totaled $179.1 million, with a free cash flow of $164.4 million. Domino's held $304.3 million in cash and equivalents as of March 23.
On&nbsp;April 23, 2025, the company's Board of Directors declared a&nbsp;$1.74&nbsp;per share quarterly dividend on its outstanding common stock for shareholders of record as of&nbsp;June 13, 2025, to be paid on&nbsp;June 30, 2025.
As of March&nbsp;23, 2025, the company's total remaining authorized amount for share repurchases was&nbsp;$764.3 million.
"Sustained market share growth reflects a company's ability to control what is under its control, a key to long term success. In the face of a challenging global macroeconomic environment, our Hungry for MORE strategic pillars are working together to drive MORE sales, MORE stores and MORE profits, annually," said CEO&nbsp;Russell Weiner.
On the company conference call, the executive mentioned that the business was impacted by the macro pressures on the lower-income consumer.
Price Action: DPZ shares are trading lower by 1.27% at $481.39 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45011035/meta-booz-allen-launch-space-llama-ai-system-for-space-station-operations" target="_blank" rel="noreferrer noopener">Meta, Booz Allen Launch' Space Llama' AI System For Space Station Operations</a></li>
</ul>
Photo by sdx15 via Shutterstock

General

Domino's Pizza Q1 Operating Margin Shrinks As Lower-Income Consumers Feel the Pinch

Wells Fargo analyst Hanwen Chang maintains Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) with a Overweight and lowers the price target from $86 to $80.

MTDR

Wells Fargo Maintains Overweight on Matador Resources, Lowers Price Target to $80

Earnings

Guidance

WETH

WeTouch Technologies Reports FY24 Prelim. EPS $0.48; Revenue $42.3M

Truist Securities analyst Joon Lee reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and lowers the price target from $95 to $75.

Reiteration

VKTX

Truist Securities Reiterates Buy on Viking Therapeutics, Lowers Price Target to $75

Strategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) announced it has acquired an additional 15,355 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) for approximately $1.42 billion <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44438245/strategy-expands-bitcoin-war-chest-with-722-million-upsized-preferred-stock-offering">between April 21 and April 27 this year.</a>
What Happened: The company paid an average price of $92,737 per Bitcoin during the purchase period, including all associated fees and expenses, according to its latest filing with the U.S. Securities and Exchange Commission.
As of April 27, Strategy now holds a total of 553,555 BTC, purchased for an aggregate cost of $37.90 billion at an average price of $68,459 per Bitcoin.
The company also reported achieving a 13.7% yield on its Bitcoin holdings year-to-date in 2025, highlighting its growing returns as Bitcoin&#8217;s market price has risen throughout the year.
The latest Bitcoin acquisition was funded through proceeds from MicroStrategy's <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43399688/microstrategy-prices-preferred-stock-offering-at-80-per-share-seeks-563m-to-buy-bitcoin">ongoing at-the-market (ATM)</a> equity offerings, including both its common stock and preferred stock sales.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45036669/bitcoin-supply-squeeze-will-drive-run-to-new-highs-bernstein">Bitcoin Supply Squeeze Will Drive Run To New Highs: Bernstein</a>
Whu It Matters: MicroStrategy remains the largest corporate holder of Bitcoin, continuing <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42870343/what-microstrategys-declining-net-asset-value-premium-really-means-for-bitcoin">its aggressive strategy</a> of using capital markets activities to expand its BTC treasury holdings.
The company&#8217;s strategy dashboard, updated regularly on its website, tracks Bitcoin purchases, holdings, and financial metrics for investors and the broader public.
Strategy's Bitcoin strategy, initiated in 2020, continues to drive its market valuation, with its stock gaining over 681% in the past year. 
The firm's inclusion in the Nasdaq 100 index has increased its visibility, attracting institutional investors. 
However, Strategy faces risks from Bitcoin's volatility and a $7.274 billion debt load, which could impact liquidity if prices decline sharply.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45034209/bitcoin-could-hit-120000-in-q2-says-standard-chartereds-geoff-kendrick">Bitcoin Could Hit $120,000 In Q2, Says Standard Chartered&#8217;s Geoff Kendrick</a></li>
</ul>
Image: Shutterstock

$BTC

MSTR

Strategy Buys 15,355 Bitcoin For $1.42 Billion, Year-To-Date BTC Yield Hits 13.7%

Wells Fargo analyst Sarah Akers maintains Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Equal-Weight and lowers the price target from $46 to $44.

Wells Fargo Maintains Equal-Weight on Portland Gen Electric, Lowers Price Target to $44

As Washington cranks up <a href="https://www.benzinga.com/topic/tariffs">the tariff pressure</a>, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) may have already played its smartest card: doubling down on India for assembly and investing deeper into U.S. component suppliers.
While the idea of building iPhones in America sounds good on paper, JPMorgan analyst Samik Chatterjee warns it's not that simple.
&#8220;The U.S. currently grapples with infrastructure and workforce limitations,&#8221; he notes &#8211; the same key ingredients that helped China become the manufacturing powerhouse it is today. Chatterjee estimates that entirely shifting iPhone assembly to the U.S. could trigger a painful 30% price increase for consumers if a 20% tariff on China is implemented.
Read Also: <a href="https://www.benzinga.com/personal-finance/25/04/45028360/if-you-invested-10k-in-apple-stock-10-years-ago-how-much-would-you-have-now">If You Invested $10K In Apple Stock 10 Years Ago, How Much Would You Have Now?</a>
<h2 class="wp-block-heading">Apple&#8217;s Best Move: Expand In India</h2>
Rather than chasing a moonshot strategy, Chatterjee believes Apple's best move is to turbocharge what it's already doing: expand in India. &#8220;Scaling further in India to address all local U.S. demand makes the most sense,&#8221; he argues, pointing to India's large skilled workforce, favorable government policies, and the ability to scale efficiently without blowing up costs.
That doesn't mean Apple will ignore the U.S. altogether. Instead, it is expected to invest more heavily in U.S.-based component makers. According to Chatterjee, this could include processors from Taiwan Semiconductor Manufacturing Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) Arizona fabs, display glass from Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>), and optical sensors from suppliers like Coherent Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) and Lumentum Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) &#8211; allowing Apple to meet political pressure without wrecking its margins.
<h2 class="wp-block-heading">Is The &#8216;Made-In-America&#8217; iPhone A Distant Dream?</h2>
A fully &#8216;Made-in-America&#8217; iPhone remains a distant dream. But a &#8220;Made-in-India, Powered-by-U.S.-Components&#8221; iPhone? That's the more likely—and smarter—reality as Apple looks to stay ahead in a world where geopolitics are increasingly shaping tech strategy.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45032214/analyst-questions-apples-reported-iphone-shift-to-india-amid-china-tariff-pressures-doesnt-solve-all-the-problems">Analyst Casts Doubt On Apple&#8217;s Reported Move To Shift iPhone Production To India Amid Rising China Tariff Pressures: &#8216;Doesn&#8217;t Solve All The Problems&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Tech

Trading Ideas

AAPL

COHR

LITE

Apple's India Game Plan Looks Smarter As Tariff Heat Rises - Analyst Highlights 4 Stocks That Could Benefit

Truist Securities analyst Peter Osterland maintains Minerals Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTX#NYSE">MTX</a>) with a Buy and lowers the price target from $92 to $80.

Truist Securities Maintains Buy on Minerals Technologies, Lowers Price Target to $80

Wells Fargo analyst David Lantz maintains Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) with a Overweight and lowers the price target from $44 to $42.

Wells Fargo Maintains Overweight on Valvoline, Lowers Price Target to $42

Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.
Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft (PDX) models.
 &nbsp;

CSBR

Champions Oncology Granted License To Use Radioactive Materials In Preclinical Studies

Stephens &amp; Co. analyst Daniel Imbro maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Overweight and lowers the price target from $275 to $255.

Stephens & Co. Maintains Overweight on Union Pacific, Lowers Price Target to $255

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has emerged as the top conviction altcoin trade according to a new report from 10x Research, citing improving market structure, technical breakouts and upcoming catalysts including the launch of <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44984259/cme-group-to-launch-xrp-futures-in-may-how-did-xrp-price-react">XRP futures on CME Group.</a>
What Happened: According to 10x Research, while Bitcoin remains capped at the $94,000–$95,000 resistance zone, attention is beginning to shift towards select altcoins.
The report states that a 50 basis-point drop in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dominance would shift the tactical altcoin outperformance indicator, signaling a broader rotation into altcoins. 
Among these, XRP is highlighted as the most favorable setup.
XRP recently broke its downtrend and recorded a 600% surge in network payment volume and transaction counts over a four-day span, with 838 million XRP transferred on April 23 alone.
This development coincides with Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) listing XRP futures contracts on its U.S. derivatives exchange, and CME Group&#8217;s announcement to launch XRP futures on May 19, pending regulatory approval.
Also Read: <a href="https://www.benzinga.com/markets/25/04/45026968/bitcoin-fundamentally-decoupled-from-us-tech-stocks-blackrocks-jay-jacobs-says">Bitcoin Fundamentally Decoupled From US Tech Stocks, BlackRock&#8217;s Jay Jacobs Says</a>
Why It Matters: The report points out that despite Bitcoin's recent rebound, funding rates have remained near zero even as open interest has risen, suggesting continued skepticism among traders and a lack of excessive leverage.
Liquidity flows, however, are materially improving, reinforcing a bullish outlook for both Bitcoin and select altcoins.
10x Research expects XRP to move higher from the $2.27 level, targeting a rally toward $2.80, supported by technical strength and expanding institutional interest. 
It also notes that Korean retail traders, historically strong participants in XRP rallies, could re-engage as momentum builds.
The firm views the current environment as an attractive window to accumulate XRP ahead of the CME futures launch, highlighting that multiple catalysts are now aligning in its favor.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45026851/bitcoin-etfs-see-442m-daily-inflow-as-btc-hovers-around-94-000">Bitcoin ETFs See $442M Daily Inflow As BTC Hovers Around $94,000</a></li>
</ul>
Image: Shutterstock

$USDT

$XRP

COIN

XRP Is The Top Altcoin Bet: 10x Research

Press Releases

Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Events

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

Palisade Bio, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Palisade Bio Participates in Virtual Investor "What This Means" Segment

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Comments

Palisade Bio

ニュース

最新ニュース Palisade Bio (NASDAQ:PALI) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル